Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies

Robert T. Means; Nancy J. Olsen; Sanford B. Krantz; Emmanuel N. Dessypris; Stanley E. Graber; William J. Stone; Vicki L. O'Neil; Theodore Pincus

doi:10.1002/anr.1780320519

Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies

Robert T. Means, Nancy J. Olsen, Sanford B. Krantz, Emmanuel N. Dessypris, Stanley E. Graber, William J. Stone, Vicki L. O'Neil, Theodore Pincus

Research output: Contribution to journal › Article › peer-review

121 Scopus citations

Abstract

Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.

Original language	English (US)
Pages (from-to)	638-642
Number of pages	5
Journal	Arthritis & Rheumatism
Volume	32
Issue number	5
DOIs	https://doi.org/10.1002/anr.1780320519
State	Published - May 1989

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Rheumatology
Immunology
Pharmacology (medical)

Access to Document

10.1002/anr.1780320519

Cite this

@article{d2b3bc3027974749b2185f92d3770cfd,

title = "Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies",

abstract = "Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.",

author = "Means, {Robert T.} and Olsen, {Nancy J.} and Krantz, {Sanford B.} and Dessypris, {Emmanuel N.} and Graber, {Stanley E.} and Stone, {William J.} and O'Neil, {Vicki L.} and Theodore Pincus",

year = "1989",

month = may,

doi = "10.1002/anr.1780320519",

language = "English (US)",

volume = "32",

pages = "638--642",

journal = "Arthritis & Rheumatism",

issn = "0004-3591",

publisher = "John Wiley and Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin

T2 - Clinical and in vitro studies

AU - Means, Robert T.

AU - Olsen, Nancy J.

AU - Krantz, Sanford B.

AU - Dessypris, Emmanuel N.

AU - Graber, Stanley E.

AU - Stone, William J.

AU - O'Neil, Vicki L.

AU - Pincus, Theodore

PY - 1989/5

Y1 - 1989/5

N2 - Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.

AB - Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0024352308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024352308&partnerID=8YFLogxK

U2 - 10.1002/anr.1780320519

DO - 10.1002/anr.1780320519

M3 - Article

C2 - 2719734

AN - SCOPUS:0024352308

SN - 0004-3591

VL - 32

SP - 638

EP - 642

JO - Arthritis & Rheumatism

JF - Arthritis & Rheumatism

IS - 5

ER -

Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this